



ASX Announcement and Media Release

Monday, April 18, 2016

SciGen Ltd

CHANGE IN THE BOARD OF DIRECTORS

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) announce a change in the Board.

APPOINTMENT OF DIRECTOR

SciGen is pleased to announce the appointment of Dr. James W Kim as an Executive Director of the Company.

Dr. Kim, the Director of Business Development and Licensing of Bioton S.A, is a graduate from the Trinity International University, Illinois. He completed his postgraduate studies and earned his doctorate in Biochemistry from the University of Wisconsin - Madison. Dr. Kim worked with LG Life Sciences Ltd serving in functions of corporate business development, diagnostics strategy & planning and business strategy for business areas including pharmaceuticals, biologicals and in vitro diagnostics. Between 2009 - 2011 he worked for Bioneer Corporation in Korea as Team Leader for molecular diagnostics technical support and Senior Scientist and Manager for the development of molecular diagnostics-based service platforms

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638